NCT05234606 2022-04-12A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsSilverback TherapeuticsPhase 1/2 Withdrawn
NCT04158700 2020-02-19A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerEli Lilly and CompanyPhase 1/2 Withdrawn